Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 5:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ziprasidone/Geodon Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial Capsules

NCT00821444
View directory record Official record
Conditions
Healthy
Interventions
ziprasidone, B16 Fasted, B16 Fed
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 22, 2026, 5:27 AM EDT
Terminated Phase 2 Interventional Results available

Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine

NCT00617058
View directory record Official record
Conditions
Weight Gain
Interventions
metformin, healthy lifestyle intervention
Drug · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
10 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 30, 2012 · Synced Sep 22, 2026, 5:27 AM EDT
Completed Phase 2 Interventional Results available

Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia

NCT00509067
View directory record Official record
Conditions
Schizophrenia
Interventions
Galantamine, CDP-choline, Placebo, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Sep 22, 2026, 5:27 AM EDT
Terminated No phase listed Observational

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

NCT02893371
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
Not listed
Enrollment
1,037,352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 22, 2026, 5:27 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia

NCT03781115
View directory record Official record
Conditions
Schizophrenia
Interventions
Ziprasidone, Olanzapine, Placebo Comparator
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 22, 2026, 5:27 AM EDT
Completed Phase 4 Interventional Results available

Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder (Zip Ad)

NCT01293825
View directory record Official record
Conditions
Medication Adherence, Bipolar Disorder
Interventions
ziprasidone
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Sep 22, 2026, 5:27 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State

NCT00490542
View directory record Official record
Conditions
Bipolar Disorder, Bipolar Depression, Depression
Interventions
ziprasidone (Geodon), placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • Cambridge, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Sep 22, 2026, 5:27 AM EDT
Completed Phase 4 Interventional

Treatment and Outcome of Early Onset Bipolar Disorder

NCT00048802
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium, Olanzapine, Divalproex, Risperidone, Quetiapine, Ziprasidone, Aripriprazole
Drug
Lead sponsor
Northwell Health
Other
Eligibility
10 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2014 · Synced Sep 22, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression

NCT00141271
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Geodon (Ziprasidone), Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
72
States / cities
Birmingham, Alabama • Dana Point, California • La Mesa, California + 60 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Sep 22, 2026, 5:27 AM EDT
Terminated Phase 4 Interventional

An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine

NCT05741502
View directory record Official record
Conditions
Treatment-resistant Schizophrenia
Interventions
Clozapine, Antipsychotics,Other (non-Clozapine)
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 22, 2026, 5:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)

NCT01172652
View directory record Official record
Conditions
Bipolar Disorder, Panic Disorder, Generalized Anxiety Disorder
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
VA Palo Alto Health Care System
Federal
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
Palo Alto, California • Tampa, Florida • Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Sep 22, 2026, 5:27 AM EDT
Terminated Phase 3 Interventional Results available

Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder

NCT03768726
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Orange City, Florida • Fayetteville, Georgia • Smyrna, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Sep 22, 2026, 5:27 AM EDT
Terminated Early Phase 1 Interventional

Reducing the Abuse of Opioids in Drug Users

NCT03837860
View directory record Official record
Conditions
Opioid Abuse, Unspecified, Opioid Dependence
Interventions
Oxycodone/Placebo, Oxycodone/Risperidone, Oxycodone/Ziprasidone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
21 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Sep 22, 2026, 5:27 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder

NCT02075047
View directory record Official record
Conditions
Bipolar Disorder
Interventions
placebo oral capsules, ziprasidone oral capsules
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
46
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Sep 22, 2026, 5:27 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

NCT03557931
View directory record Official record
Conditions
Schizophrenia
Interventions
ASP4345, placebo, risperidone, quetiapine, olanzapine, ziprasidone, aripiprazole, brexpiprazole, paliperidone, lurasidone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
27
States / cities
Cerritos, California • Garden Grove, California • Lemon Grove, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 22, 2026, 5:27 AM EDT
Not listed Phase 4 Interventional

Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia

NCT02282085
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole Once-Monthly, Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
Drug
Lead sponsor
Matt Byerly
Other
Eligibility
18 Years to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 22, 2026, 5:27 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression

NCT00340379
View directory record Official record
Conditions
Affective Disorders
Interventions
Ziprasidone, Sertraline, Haloperidol
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Sep 22, 2026, 5:27 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Reducing the Abuse Liability of Prescription Opioids

NCT04587115
View directory record Official record
Conditions
Addiction
Interventions
Risperidone, Ziprasidone, Oxycodone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
21 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 22, 2026, 5:27 AM EDT
Completed Not applicable Interventional Results available

Glucose and Lipid Metabolism on Antipsychotic Medication

NCT00515723
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Type 2 Diabetes Mellitus, Hyperglycemia
Interventions
risperidone, olanzapine, quetiapine, ziprasidone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Sep 22, 2026, 5:27 AM EDT
Not listed No phase listed Observational

DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics

NCT00752960
View directory record Official record
Conditions
Psychoses
Interventions
Not listed
Lead sponsor
Genomas, Inc
Industry
Eligibility
18 Years to 59 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Hartford, Connecticut • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 15, 2008 · Synced Sep 22, 2026, 5:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pfizer/IVGTT/Ziprasidone/Olanzapine

NCT00205725
View directory record Official record
Conditions
Schizophrenia, Type 2 Diabetes Mellitus
Interventions
Ziprasidone, Olanzapine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Sep 22, 2026, 5:27 AM EDT
Completed Phase 4 Interventional Results available

Ziprasidone in Pediatric Bipolar Disorder

NCT00622739
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ziprasidone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
10 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Sep 22, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study

NCT01211522
View directory record Official record
Conditions
Delirium, Impaired Cognition, Long Term Psychologic Disorders
Interventions
Haloperidol, Ziprasidone, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
16
States / cities
Denver, Colorado • New Haven, Connecticut • Indianapolis, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 22, 2026, 5:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism

NCT02237417
View directory record Official record
Conditions
Schizophrenia
Interventions
Standard of Care Oral antipsychotics, IM aripiprazole once monthly, No Treatment
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 22, 2026, 5:27 AM EDT